卵巢癌紫杉醇耐药机制与TLR4/MyD88信号通路相关性的研究进展

Research progress of the correlation between paclitaxel resistance mechanism for treating ovarian cancer and TLR4/MyD88 signaling pathway

卵巢癌是造成女性死亡的常见肿瘤之一,作为一种异质性疾病具有复杂的分子和遗传变化。卵巢癌复发率相对较高,了解其相关耐药机制及利用肿瘤的特定变化合理靶向治疗至关重要。Toll样受体(TLR4)不仅在免疫细胞上表达,也在肿瘤细胞尤其是卵巢癌上表达。初级应答基因88(MyD88)最近也被证明可以促进自发和致癌物质诱导的(丙氧基甲烷)肿瘤发生。紫杉醇是治疗卵巢癌的重要药物之一,作为TLR4的主要配体可激活TLR4/MyD88信号通路,在癌细胞的增殖、凋亡等方面发挥重要作用。本文主要阐述了卵巢癌紫杉醇耐药与TLR4/MyD88信号通路相关性的研究进展,以期为临床诊疗提供参考。

Ovarian cancer is one of the most common cancers that cause death of women.It is a heterogeneous disease with complex molecular and genetic changes.The recurrence rate of ovarian cancer is relatively high,so it is important to understand the related mechanisms of drug resistance and to base on the specific changes of the tumor to target therapy more rationally.The Toll-like receptor TLR4 is expressed not only in immune cell,but also in tumor cells,especially in ovarian cancer cells.MyD88 has also recently been shown to promote both spontaneous and carcinogenic(propoxymethane)tumorigenesis.Paclitaxel is one of the important drugs for the treatment of ovarian cancer.As a major ligand of TLR4,paclitaxel activates the TLR4/MyD88 signaling pathway,and plays an important role in the proliferation and apoptosis of cancer cells.This paper mainly reviewed the research progress of the correlation between paclitaxel resistance for ovarian cancer and TLR4/MyD88 signaling pathway,in order to provide reference for clinical diagnosis and treatment.